


-93-

WE CLAIM:

1. An indole compound represented by the formula (I),
 or a pharmaceutically acceptable salt, solvate, or prodrug
 5 derivative thereof;



wherein ;

- 10 R_1 is selected from groups (a), (b), and (c) wherein;

(a) is C7-C20 alkyl, C7-C20 haloalkyl, C7-C20 alkenyl, C7-C20 alkynyl, carbocyclic radical, or heterocyclic radical, or

- (b) is a member of (a) substituted with one or
 15 more independently selected non-interfering substituents;
 or


(c) is the group $-(L_1)-R_{11}$; where, $-(L_1)-$ is a divalent linking group of 1 to 8 atoms and where R_{11} is a group selected from (a)

- 20 or (b);

R_2 is hydrogen, or a group containing 1 to 4 non-hydrogen atoms plus any required hydrogen atoms;



- R_3 is $-(L_3)-Z$, where $-(L_3)-$ is a divalent linker group selected from a bond or a divalent group selected
 25 from:

-94-




and Z is selected from a group represented by the formulae,

5



10

or



10069824.022403

-95-

wherein, X is oxygen or sulfur; and R_a is selected from hydrogen, C₁-C₈ alkyl, aryl, C₁-C₈ alkaryl, C₁-C₈ alkoxy, aralkyl and -CN;

R₄ is the group, -(L_h)-(hydroxyfunctional amide);


5 wherein -(L_h)-, is an hydroxyfunctional amide linker having an hydroxyfunctional amide linker length of 1 to 8;

R₅ is selected from hydrogen, a non-interfering substituent, or the group, -(L_a)-(acidic group); wherein -(L_a)-, is an acid linker having an acid linker length of 1
10 to 8;

R₆ and R₇ are selected from hydrogen, non-interfering substituent, carbocyclic radical, carbocyclic radical substituted with non-interfering substituent(s), heterocyclic radicals, and heterocyclic radical substituted
15 with non-interfering substituent(s).

2. The compound of claim 1 wherein R₂ is hydrogen, C₁-C₄ alkyl, C₂-C₄ alkenyl, -O-(C₁-C₃ alkyl), -S-(C₁-C₃ alkyl), C₃-C₄ cycloalkyl, -CF₃, halo, -NO₂, -CN, or -SO₃.

3. The compound of Claim 1 wherein the hydroxyfunctional amide linker group, -(L_h)-, for R₄ is selected from a group represented by the formula;







where Q₂ is selected from the group -(CH₂)-, -O-, -NH-, -C(O)-, and -S-, and each R₄₀ is independently selected


-96-

from hydrogen, C₁-C₈ alkyl, aryl, C₁-C₈ alkaryl, C₁-C₈ alkoxy, aralkyl, and halo.

4. The compound of Claim 1 wherein the
 5 hydroxyfunctional amide linker group, -(Lh)-, for R₄ is a divalent group selected from,




-97-








where R_{40} , R_{41} , R_{42} , and R_{43} are each independently
 5 selected from hydrogen, C_1 - C_8 alkyl.

5. The compound of Claim 1 wherein the acid linker,
 $-(L_a)-$, for R_5 is selected from a group represented by the
 formulae consisting of;




-98-




10069824.022102

-99-



and




wherein R₅₄, R₅₅, R₅₆ and R₅₇ are each independently hydrogen, C₁-C₈ alkyl, C₁-C₈ haloalkyl, aryl, C₁-C₈ alkoxy, or halo.





6. The compound of claim 1 wherein R₅ is the group, -(L_a)-(acidic group) and wherein the (acidic group) is selected from the group:

-5-tetrazolyl,

-SO₃H,




-100-



201220" 42859001


-101-



where R_{80} is a metal or C_1 - C_8 alkyl and R_{81} is an organic substituent or $-CF_3$.

5


7. The compound of claim 1 wherein for R_3 , Z is the group represented by the formula;



10 and the linking group $-(L_3)-$ is a bond; and R_a is hydrogen, methyl, ethyl, propyl, isopropyl, phenyl or benzyl.


15 8. The compound of claim 1 wherein for R_3 , Z is the group represented by the formula;

-102-



and the linking group $-(L_3)-$ is a bond; and R_a is hydrogen.


- 5 9. The compound of claim 1 wherein for R_3 , Z is the group represented by the formula;



and the linking group $-(L_3)-$ is a bond.

10

10. The compound of claim 1 wherein for R_3 , Z is the group represented by the formula;



- 15 and the linking group $-(L_3)-$ is a bond.



11. The compound of Claim 1 wherein, for R_6 the non-interfering substituent is hydrogen, C₁-C₈ alkyl, C₂-C₈ alkenyl, C₂-C₈ alkynyl, C₇-C₁₂ aralkyl, C₇-C₁₂ alkaryl, C₃-C₈ cycloalkyl, C₃-C₈ cycloalkenyl, phenyl, tolulyl, xylenyl, biphenyl, C₁-C₈ alkoxy, C₂-C₈ alkenyloxy, C₂-C₈ alkynyloxy, C₂-C₁₂ alkoxyalkyl, C₂-C₁₂ alkoxyalkyloxy, C₂-C₁₂ alkylcarbonyl, C₂-C₁₂ alkylcarbonylamino, C₂-C₁₂ alkoxyamino, C₂-C₁₂ alkoxyaminocarbonyl, C₁-C₁₂

10069824, 022103


-103-

alkylamino, C₁-C₆ alkylthio, C₂-C₁₂ alkylthiocarbonyl,
 C₁-C₈ alkylsulfinyl, C₁-C₈ alkylsulfonyl, C₂-C₈
 haloalkoxy, C₁-C₈ haloalkylsulfonyl, C₂-C₈ haloalkyl,
 C₁-C₈ hydroxyalkyl, -C(O)O(C₁-C₈ alkyl), -(CH₂)_n-O-(C₁-C₈
 5 alkyl), benzyloxy, phenoxy, phenylthio, -(CONHSO₂R), -CHO,
 amino, amidino, bromo, carbamyl, carboxyl, carbalkoxy,
 -(CH₂)_n-CO₂H, chloro, cyano, cyanoguanidiny, fluoro,
 guanidino, hydrazide, hydrazino, hydrazido, hydroxy,
 hydroxyamino, iodo, nitro, phosphono, -SO₃H, thioacetal,
 10 thiocarbonyl, or carbonyl; where n is from 1 to 8.

12. The compound of Claim 1 wherein for R₁ the
 divalent linking group -(L₁)- is selected from a group
 represented by the formulae (Ia), (Ib), (Ic), (Id), (Ie),
 15 and (If):



or



"10069824-022102"


-104-

where Q_1 is a bond or any of the divalent groups Ia, Ib, Ic, Id, and Ie and R_{10} is independently -H, C_{1-8} alkyl, C_{1-8} haloalkyl or C_{1-8} alkoxy.

5

13. The compound of claim 1 wherein the linking group $-(L_1)-$ of R_1 is $-(CH_2)-$ or $-(CH_2-CH_2)-$.

10 14. The compound of claim 1 wherein the linking group $-(L_{11})-$ of R_{11} is a bond and R_{11} is $-(CH_2)_m-R^{12}$ wherein m is an integer from 1 to 6, and R^{12} is a group represented by the formula:




15 wherein $a, c, e, n, q,$ and t are independently an integer from 0 to 2, R^{13} and R^{14} are independently selected from a halogen, C_1 to C_8 alkyl, C_1 to C_8 alkyloxy, C_1 to C_8 alkylthio, aryl, heteroaryl, and C_1 to C_8 haloalkyl, α is an oxygen atom or a sulfur atom, L^5 is a bond, $-(CH_2)_v-$,

10069824.022402

-105-

-C=C-, -CC-, -O-, or -S-, v is an integer from 0 to 2, β is -CH₂- or -(CH₂)₂-, γ is an oxygen atom or a sulfur atom, b is an integer from 0 to 3, d is an integer from 0 to 4, f, p, and w are independently an integer from 0 to 5, r is an integer from 0 to 7, and u is an integer from 0 to 4, or is (e) a member of (d) substituted with at least one substituent selected from the group consisting of C₁ to C₆ alkyl, C₁ to C₈ alkyloxy, C₁ to C₈ haloalkyloxy, C₁ to C₈ haloalkyl, aryl, and a halogen..


15. The compound of claim 1 wherein for R₁ the group R₁₁ is a substituted or unsubstituted carbocyclic radical selected from the group consisting of cycloalkyl, cycloalkenyl, phenyl, spiro[5.5]undecanyl, naphthyl, norbornanyl, bicycloheptadienyl, tolulyl, xylenyl, indenyl, stilbenyl, terphenyl, diphenylethylenyl, phenyl-cyclohexenyl, acenaphthylenyl, and anthracenyl, biphenyl, bibenzyl and related bibenzyl homologues represented by the formula (a):




where n is a number from 1 to 8.

16. The compound of Claim 12 wherein for R₁ the combined group -(L₁)-R₁₁ is selected from the groups;

-106-



or




where R_{12} is a radical independently selected from halo, C_1 - C_{10} alkyl, C_1 - C_{10} alkoxy, $-S-(C_1-C_{10} \text{ alkyl})$, and C_1 - C_{10} haloalkyl, C_1 - C_{10} hydroxyalkyl and t is a number from 0 to 5 and u is a number from 0 to 4.

17. The compound of claim 1 wherein for R_1 the radical R_{11} is a substituted or unsubstituted heterocyclic radical selected from pyrrolyl, pyrrolodiny, piperidiny, furanyl, thiophenyl, pyrazolyl, imidazolyl, phenylimidazolyl, triazolyl, isoxazolyl, oxazolyl, thiazolyl, thiadiazolyl, indolyl, carbazolyl, norharmanyl, azaindolyl, benzofuranyl, dibenzofuranyl, dibenzothiophenyl, indazolyl, imidazo(1,2-A)pyridiny, benzotriazolyl, anthranilyl, 1,2-benzisoxazolyl, benzoxazolyl, benzothiazolyl, puriny, pyridiny, dipyridylyl, phenylpyridiny, benzylpyridiny, pyrimidiny, phenylpyrimidiny, pyraziny, 1,3,5-triaziny, quinoliny, phthalaziny, quinazolinyl-morpholino, thiomorpholino, homopiperaziny, tetrahydrofuranyl, tetrahydropyranyl, oxacanyl, 1,3-dioxolanyl, 1,3-dioxanyl, 1,4-dioxanyl, tetrahydrothiopheneyl, pentamethylenesulfadyl, 1,3-dithianyl, 1,4-dithianyl, 1,4-thioxanyl, azetidiny,

-107-

hexamethyleneiminium, heptamethyleneiminium, piperazinyl or quinoxalinylyl.

18. The compound of claim 1 wherein R₄ is the group,
5 -(L_C)-(hydroxyfunctional amide group) and wherein the
(hydroxyfunctional amide group) is:



10


15

and R^{4a} is independently selected from the group consisting of OH, (C₁-C₆)alkoxy, (C₇-C₁₄)alkaryloxy, (C₂-C₈)alkenyloxy, (C₇-C₁₄) aralkyloxy, (C₇-C₁₄)aralkenyloxy and aryloxy; and wherein R^{4b} is independently selected from the group
15 consisting of H, (C₁-C₆)alkyl, arylalkyl, heteroaryl and aryl.

20

19. An indole compound represented by the
formula (II), or a pharmaceutically acceptable salt,
20 solvate, or prodrug derivative thereof;

-108-





wherein ;



5 R₂₂ is selected from hydrogen, methyl, ethyl, propyl, isopropyl, cyclopropyl, -F, -CF₃, -Cl, -Br, or -O-CH₃;

 R_{4a} is independently selected from the group consisting of OH, (C₁-C₆)alkoxy, (C₇-C₁₄)alkaryloxy, (C₂-C₈)alkenyloxy, (C₇-C₁₄) aralkyloxy, (C₇-C₁₄)aralkenyloxy and aryloxy; and


10 R_{4b} is H, (C₁-C₆)alkyl, arylalkyl, heteroaryl or aryl ;
and -(L_h)- is a divalent group selected from;



-109-



or



- 5 where R_{40} , R_{41} , R_{42} , and R_{43} are each independently selected from hydrogen or C₁-C₈ alkyl.

R_{16} is selected from hydrogen, C₁-C₈ alkyl, C₁-C₈ alkoxy, C₁-C₈ alkylthio C₁-C₈ haloalkyl, C₁-C₈ hydroxyalkyl, and halo.

R_{13} is selected from hydrogen and C₁-C₈ alkyl, C₁-C₈ alkoxy, -S-(C₁-C₈ alkyl), C₁-C₈ haloalkyl, C₁-C₈ hydroxyalkyl, phenyl, halophenyl, and halo, and t is an integer from 0 to 5.

20. A compound of claim 1 selected from the group consisting of:

-110-

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(hydroxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(methyloxy)acetamide;

5 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(methyl)-N-(methyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(hydroxy)-N-(methyl)acetamide;

10 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(ethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(2-propenyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(hydroxy)-N-(2-propyl)acetamide;

15 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(tert-butyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-[2-(methyl)propyloxy]acetamide;

20 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(methyl)-N-(phenylmethyloxy)acetamide;

2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(phenyloxy)acetamide;

25 2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(methyl)-N-(phenyloxy)acetamide;


2-[[3-(Aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(cyclohexyl)-N-(hydroxy)acetamide; and

30 2-[[3-(2-Amino-2-oxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]-N-(hydroxy)acetamide.


10069824.022102

-111-


21. An indole compound represented by the formulae (C1), (C2), (C3), (C4), (C5), (C6), (C7), (C8), (C9), (C10), (C11), (C12), (C13), (C14) or (C15);



(C1) ,







(C2) ,



(C3) ,




201220142359001

-112-






10069824.022103

-113-




10059624.022102

-114-




10065824.022402

-115-



(C14), and



(C15)

5

or pharmaceutically acceptable salts or prodrugs thereof.

22. A pharmaceutical formulation comprising a indole compound as claimed in claim 1 together with a
10 pharmaceutically acceptable carrier or diluent therefor.

23. A method of inhibiting sPLA₂ mediated release of fatty acid comprising: contacting sPLA₂ with a therapeutically effective amount of indole compound as
15 claimed in claim 1.

24. A method of treating a mammal, including a human, to alleviate the pathological effects of Inflammatory Diseases; wherein the method comprises
20 administering to said mammal a thrapeutically effective amount of an indole compound as claimed in Claim 1.

1069824.022102

-116-

25. A compound of claim 1 or a pharmaceutical formulation containing an effective amount of the compound of claim 1 useful for the treatment and/or amelioration of
5 Inflammatory Diseases.

26. A compound of claim 1 or a pharmaceutical formulation containing an effective amount of the compound of claim 1 for useful for inhibiting sPLA₂ mediated
10 release of fatty acid.

27. Use of a pharmaceutical composition comprising sPLA₂ inhibitor compounds according to Claim 1 and mixtures thereof for the manufacture of a medicament for
15 the treatment of Inflammatory Diseases.

20120120 14283001